305 related articles for article (PubMed ID: 29502931)
1. Effect of Radiation Treatment Volume Reduction on Lymphopenia in Patients Receiving Chemoradiotherapy for Glioblastoma.
Rudra S; Hui C; Rao YJ; Samson P; Lin AJ; Chang X; Tsien C; Fergus S; Mullen D; Yang D; Thotala D; Hallahan D; Campian JL; Huang J
Int J Radiat Oncol Biol Phys; 2018 May; 101(1):217-225. PubMed ID: 29502931
[TBL] [Abstract][Full Text] [Related]
2. Clinical predictors of radiation-induced lymphopenia in patients receiving chemoradiation for glioblastoma: clinical usefulness of intensity-modulated radiotherapy in the immuno-oncology era.
Byun HK; Kim N; Yoon HI; Kang SG; Kim SH; Cho J; Baek JG; Chang JH; Suh CO
Radiat Oncol; 2019 Mar; 14(1):51. PubMed ID: 30917849
[TBL] [Abstract][Full Text] [Related]
3. Clinical and Dosimetric Predictors of Acute Severe Lymphopenia During Radiation Therapy and Concurrent Temozolomide for High-Grade Glioma.
Huang J; DeWees TA; Badiyan SN; Speirs CK; Mullen DF; Fergus S; Tran DD; Linette G; Campian JL; Chicoine MR; Kim AH; Dunn G; Simpson JR; Robinson CG
Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):1000-1007. PubMed ID: 26025775
[TBL] [Abstract][Full Text] [Related]
4. Phase I three-dimensional conformal radiation dose escalation study in newly diagnosed glioblastoma: Radiation Therapy Oncology Group Trial 98-03.
Tsien C; Moughan J; Michalski JM; Gilbert MR; Purdy J; Simpson J; Kresel JJ; Curran WJ; Diaz A; Mehta MP;
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):699-708. PubMed ID: 18723297
[TBL] [Abstract][Full Text] [Related]
5. Impact of overall corticosteroid exposure during chemoradiotherapy on lymphopenia and survival of glioblastoma patients.
Hui CY; Rudra S; Ma S; Campian JL; Huang J
J Neurooncol; 2019 May; 143(1):129-136. PubMed ID: 30864102
[TBL] [Abstract][Full Text] [Related]
6. Association between treatment-related lymphopenia and overall survival in elderly patients with newly diagnosed glioblastoma.
Mendez JS; Govindan A; Leong J; Gao F; Huang J; Campian JL
J Neurooncol; 2016 Apr; 127(2):329-35. PubMed ID: 26725885
[TBL] [Abstract][Full Text] [Related]
7. Association between treatment-related lymphopenia and survival in glioblastoma patients following postoperative chemoradiotherapy.
Mapelli R; Julita C; Bianchi SP; Gallina N; Lucchini R; Midulla M; Puci F; Saddi J; Trivellato S; Panizza D; De Ponti E; Arcangeli S
Strahlenther Onkol; 2022 May; 198(5):448-457. PubMed ID: 34617129
[TBL] [Abstract][Full Text] [Related]
8. Initial Results of a Phase 2 Trial of
Laack NN; Pafundi D; Anderson SK; Kaufmann T; Lowe V; Hunt C; Vogen D; Yan E; Sarkaria J; Brown P; Kizilbash S; Uhm J; Ruff M; Zakhary M; Zhang Y; Seaberg M; Wan Chan Tseung HS; Kabat B; Kemp B; Brinkmann D
Int J Radiat Oncol Biol Phys; 2021 Aug; 110(5):1383-1395. PubMed ID: 33771703
[TBL] [Abstract][Full Text] [Related]
9. The Assessment of Clinical Outcomes and Prognostic Factors in Glioblastoma Patients.
Demircan NV; Erpolat OP; Guzel C; Senturk E; Bora H; Karahacioglu E
Turk Neurosurg; 2023; 33(5):870-886. PubMed ID: 37528719
[TBL] [Abstract][Full Text] [Related]
10. Does Unintentional Splenic Radiation Predict Outcomes After Pancreatic Cancer Radiation Therapy?
Chadha AS; Liu G; Chen HC; Das P; Minsky BD; Mahmood U; Delclos ME; Suh Y; Sawakuchi GO; Beddar S; Katz MH; Fleming JB; Javle MM; Varadhachary GR; Wolff RA; Crane CH; Wang X; Thames H; Krishnan S
Int J Radiat Oncol Biol Phys; 2017 Feb; 97(2):323-332. PubMed ID: 28068240
[TBL] [Abstract][Full Text] [Related]
11. Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years.
Ohno M; Miyakita Y; Takahashi M; Igaki H; Matsushita Y; Ichimura K; Narita Y
Radiat Oncol; 2019 Nov; 14(1):200. PubMed ID: 31718669
[TBL] [Abstract][Full Text] [Related]
12. Dexamethasone administration during definitive radiation and temozolomide renders a poor prognosis in a retrospective analysis of newly diagnosed glioblastoma patients.
Shields LB; Shelton BJ; Shearer AJ; Chen L; Sun DA; Parsons S; Bourne TD; LaRocca R; Spalding AC
Radiat Oncol; 2015 Oct; 10():222. PubMed ID: 26520780
[TBL] [Abstract][Full Text] [Related]
13. A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients With Glioblastoma.
Krauze AV; Myrehaug SD; Chang MG; Holdford DJ; Smith S; Shih J; Tofilon PJ; Fine HA; Camphausen K
Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):986-992. PubMed ID: 26194676
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of moderately hypofractionated simultaneous integrated boost intensity-modulated radiotherapy combined with temozolomide for the postoperative treatment of glioblastoma multiforme: a single-institution experience.
Zhong L; Chen L; Lv S; Li Q; Chen G; Luo W; Zhou P; Li G
Radiat Oncol; 2019 Jun; 14(1):104. PubMed ID: 31196126
[TBL] [Abstract][Full Text] [Related]
15. Retrospective comparison of standard and escalated doses of radiotherapy in newly diagnosed glioblastoma patients treated with concurrent and adjuvant temozolomide.
Guler OC; Yıldırım BA; Önal C; Topkan E
Indian J Cancer; 2019; 56(1):59-64. PubMed ID: 30950447
[TBL] [Abstract][Full Text] [Related]
16. Standard (60 Gy) or short-course (40 Gy) irradiation plus concomitant and adjuvant temozolomide for elderly patients with glioblastoma: a propensity-matched analysis.
Minniti G; Scaringi C; Lanzetta G; Terrenato I; Esposito V; Arcella A; Pace A; Giangaspero F; Bozzao A; Enrici RM
Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):109-15. PubMed ID: 25442339
[TBL] [Abstract][Full Text] [Related]
17. Hypofractionated radiation therapy versus standard fractionated radiation therapy with concurrent temozolomide in elderly patients with newly diagnosed glioblastoma.
Wang TJC; Wu CC; Jani A; Estrada J; Ung T; Chow DS; Soun JE; Saad S; Qureshi YH; Gartrell R; Saadatmand HJ; Saraf A; Garrett MD; Grubb C; Isaacson SR; Cheng SK; Sisti MB; Bruce JN; Sheth SA; Lassman AB; Iwamoto FM; McKhann GM
Pract Radiat Oncol; 2016; 6(5):306-314. PubMed ID: 26952813
[TBL] [Abstract][Full Text] [Related]
18. Hypofractionated accelerated radiotherapy (HART) with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma: a phase II randomized trial (HART-GBM trial).
Mallick S; Kunhiparambath H; Gupta S; Benson R; Sharma S; Laviraj MA; Upadhyay AD; Julka PK; Sharma D; Rath GK
J Neurooncol; 2018 Oct; 140(1):75-82. PubMed ID: 29936695
[TBL] [Abstract][Full Text] [Related]
19. Clinical observation of lymphopenia in patients with newly diagnosed glioblastoma.
Kim WJ; Dho YS; Ock CY; Kim JW; Choi SH; Lee ST; Kim IH; Kim TM; Park CK
J Neurooncol; 2019 Jun; 143(2):321-328. PubMed ID: 30982199
[TBL] [Abstract][Full Text] [Related]
20. Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol.
Souhami L; Seiferheld W; Brachman D; Podgorsak EB; Werner-Wasik M; Lustig R; Schultz CJ; Sause W; Okunieff P; Buckner J; Zamorano L; Mehta MP; Curran WJ
Int J Radiat Oncol Biol Phys; 2004 Nov; 60(3):853-60. PubMed ID: 15465203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
